Biocept, Inc.

Biocept, Inc., incorporated on June 28, 2013, is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s breast, lung and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on characteristics of their patients’ tumors.The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer.

Bank Name Biocept, Inc.
Stock Exchange NASDAQ
Symbol BIOC
Sector Healthcare
Industry Medical Specialities
Country United States
World Region America
Chairman
CEO Mr. Michael W. Nall
Employees 94
Website www.biocept.com
Registered Year 1997

UpdateContent
UpdateContent
UpdateContent